222 related articles for article (PubMed ID: 35921451)
1. Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G; Taylor KI; Anzures-Cabrera J; Marchesi M; Simuni T; Marek K; Postuma RB; Pavese N; Stocchi F; Azulay JP; Mollenhauer B; López-Manzanares L; Russell DS; Boyd JT; Nicholas AP; Luquin MR; Hauser RA; Gasser T; Poewe W; Ricci B; Boulay A; Vogt A; Boess FG; Dukart J; D'Urso G; Finch R; Zanigni S; Monnet A; Pross N; Hahn A; Svoboda H; Britschgi M; Lipsmeier F; Volkova-Volkmar E; Lindemann M; Dziadek S; Holiga Š; Rukina D; Kustermann T; Kerchner GA; Fontoura P; Umbricht D; Doody R; Nikolcheva T; Bonni A; ;
N Engl J Med; 2022 Aug; 387(5):421-432. PubMed ID: 35921451
[TBL] [Abstract][Full Text] [Related]
2. Trial of Cinpanemab in Early Parkinson's Disease.
Lang AE; Siderowf AD; Macklin EA; Poewe W; Brooks DJ; Fernandez HH; Rascol O; Giladi N; Stocchi F; Tanner CM; Postuma RB; Simon DK; Tolosa E; Mollenhauer B; Cedarbaum JM; Fraser K; Xiao J; Evans KC; Graham DL; Sapir I; Inra J; Hutchison RM; Yang M; Fox T; Budd Haeberlein S; Dam T;
N Engl J Med; 2022 Aug; 387(5):408-420. PubMed ID: 35921450
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
Front Neurol; 2021; 12():705407. PubMed ID: 34659081
[No Abstract] [Full Text] [Related]
4. Trial of Deferiprone in Parkinson's Disease.
Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
[TBL] [Abstract][Full Text] [Related]
5. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
Hutchison RM; Fraser K; Yang M; Fox T; Hirschhorn E; Njingti E; Scott D; Bedell BJ; Kistner KM; Cedarbaum JM; Evans KC; Graham D; Martarello L; Mollenhauer B; Lang AE; Dam T; Beaver J
Neurology; 2024 Mar; 102(5):e209137. PubMed ID: 38315945
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
7. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
8. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A; Rosanbalm S; Leinonen M; Olanow CW; To D; Bell A; Lee D; Chang J; Dubow J; Dhall R; Burdick D; Parashos S; Feuerstein J; Quinn J; Pahwa R; Afshari M; Ramirez-Zamora A; Chou K; Tarakad A; Luca C; Klos K; Bordelon Y; St Hiliare MH; Shprecher D; Lee S; Dawson TM; Roschke V; Kieburtz K
Lancet Neurol; 2024 Jan; 23(1):37-45. PubMed ID: 38101901
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
[TBL] [Abstract][Full Text] [Related]
15. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
[TBL] [Abstract][Full Text] [Related]
16. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Verschuur CVM; Suwijn SR; Boel JA; Post B; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Munts AG; Deuschl G; Lang AE; Dijkgraaf MGW; de Haan RJ; de Bie RMA;
N Engl J Med; 2019 Jan; 380(4):315-324. PubMed ID: 30673543
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
[TBL] [Abstract][Full Text] [Related]
18. Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.
Oertel WH; Müller HH; Unger MM; Schade-Brittinger C; Balthasar K; Articus K; Brinkman M; Venuto CS; Tracik F; Eberling J; Eggert KM; Kamp C; Kieburtz K; Boyd JT
NEJM Evid; 2023 Sep; 2(9):EVIDoa2200311. PubMed ID: 38320207
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
Schapira AH; McDermott MP; Barone P; Comella CL; Albrecht S; Hsu HH; Massey DH; Mizuno Y; Poewe W; Rascol O; Marek K
Lancet Neurol; 2013 Aug; 12(8):747-55. PubMed ID: 23726851
[TBL] [Abstract][Full Text] [Related]
20. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
